Biotech company Q BioMed is reporting sales progress from the launch of its Strontium89 (strontium-89 chloride injection) metastatic bone cancer palliation radiopharmaceutical.
Freestanding clinics in at least eight U.S. states are now undergoing the required operational steps to utilize Strontium89, including having it on their radioactive materials license, according to the firm. Several of these sites are already treating patients, Q BioMed said.
The company launched Strontium89 in the U.S. in the first quarter. With full Medicare and Medicaid reimbursement of Strontium89 treatments in the hospital outpatient setting taking effect in October, Q BioMed said it expects to see hospitals more actively treat patients.
The company said it also debuted its international "Named Patient" program, which allows physicians worldwide to order Strontium89 for their patients in need. Orders have already been received in the U.K., and additional orders are pending from at least seven other countries, according to the company. Q BioMed said it has begun the regulatory registration process to gain full commercial access to the EU and hopes to receive approval by the end of the year.
What's more, Q BioMed said it's halfway through the registration process in many other countries, with approvals expected to begin in October and continue through the first quarter of 2021.
